The emergence of artemisinin partial resistance in Africa: how do we respond?
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
Malaria remains one of the most important infectious diseases in the world, with the greatest burden in sub-Saharan Africa, primarily from Plasmodium falciparum infection. The treatment and control of malaria is challenged by resistance to most available drugs, but partial resistance to artemisinins (ART-R), the most important class for the treatment of malaria, was until recently confined to southeast Asia. This situation has changed, with the emergence of ART-R in multiple countries in eastern Africa. ART-R is mediated primarily by single point mutations in the P falciparum kelch13 protein, with several mutations present in African parasites that are now validated resistance mediators based on clinical and laboratory criteria. Major priorities at present are the expansion of genomic surveillance for ART-R mutations across the continent, more frequent testing of the efficacies of artemisinin-based regimens against uncomplicated and severe malaria in trials, more regular assessment of ex-vivo antimalarial drug susceptibilities, consideration of changes in treatment policy to deter the spread of ART-R, and accelerated development of new antimalarial regimens to overcome the impacts of ART-R. The emergence of ART-R in Africa is an urgent concern, and it is essential that we increase efforts to characterise its spread and mitigate its impact.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Artemisinin Resistance in Plasmodium falciparum Malaria
Dondorp, A. M., Nosten, F., Yi, P., Das, D., Phyo, A. P., Tarning, J., Lwin, K. M., Ariey, F., Hanpithakpong, W., Lee, S. J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808859 · Cited by 3,424
Qinghaosu (Artemisinin): The Price of Success
White, N. J. (2008) · Science · doi:10.1126/science.1155165 · Cited by 954
Seasonal Malaria Vaccination with or without Seasonal Malaria Chemoprevention
Chandramohan, D., Zongo, I., Sagara, I., Cairns, M., Yerbanga, R.-S., Diarra, M., Nikièma, F., Tapily, A., Sompougdou, F., Issiaka, D., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2026330 · Cited by 236
Cissé, B., Ba, E. H., Sokhna, C., NDiaye, J. L., Gomis, J. F., Dial, Y., Pitt, C., NDiaye, M., Cairns, M., Faye, E., et al. (2016) · PLoS Medicine · doi:10.1371/journal.pmed.1002175 · Cited by 191
Pregnancy and malaria: The perfect storm
Rogerson, S. J., & Unger, H. W. (2022) · Current Opinion in Infectious Diseases · doi:10.1097/qco.0000000000000859 · Cited by 17
Cited by
Ogieuhi, I. J., Ajekiigbe, V. O., Kolo-Manma, K., Akingbola, A., Odeniyi, T. A., Soyemi, T. S., Ayomide, J. H., Thiyagarajan, B., & Awolola, B. D. (2024) · Discover Public Health · doi:10.1186/s12982-024-00284-w · Cited by 13
Mechanistic insights into dual-active liver and blood-stage antiplasmodials
(2025) · doi:10.1128/mbio.02423-25
Metadata
- Authors
- Rosenthal, P. J., Asua, V., Bailey, J. A., Conrad, M. D., Ishengoma, D. S., Kamya, M. R., Rasmussen, C., Tadesse, F. G., Uwimana, A., & Fidock, D. A.
- Venue
- The Lancet Infectious Diseases
- Publisher
- Elsevier BV
- Published
- 2024-09
- Volume
- 24
- Issue
- 9
- Pages
- e591-e600
- ISSN
- 1473-3099 (ISSN-L)
- OpenAlex
- W4393183623
- Cited by
- 180
- References
- 5
- FWCI
- 68.13
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The emergence of artemisinin partial resistance in Africa: how do we respond? https://app.cochat.ai/papers/10.1016/s1473-3099(24)00141-5
- The paper
- Rosenthal, P. J., Asua, V., Bailey, J. A., Conrad, M. D., Ishengoma, D. S., Kamya, M. R., Rasmussen, C., Tadesse, F. G., Uwimana, A., & Fidock, D. A. (2024). The emergence of artemisinin partial resistance in Africa: how do we respond? The Lancet Infectious Diseases. https://doi.org/10.1016/s1473-3099(24)00141-5
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.